| Page 916 | Kisaco Research
 

Mary Guzman

Founder, CEO and Risk Management Consultant
Crown Jewel Insurance

Mary Guzman is an insurance industry veteran and pioneer. She has over 25 years experience advising clients on a myriad of risks to their businesses, most recently with a focus on all things related to technology, media, and intellectual property. Mary is an industry trailblazer and disrupter. Mary was one of the first in the industry to develop a cyber insurance policy in 2000. She is a published author and speaker, having done over 125 speaking engagements on risks/solutions to threats arising from the convergence of all things intangible.

Mary Guzman

Founder, CEO and Risk Management Consultant
Crown Jewel Insurance

Mary Guzman

Founder, CEO and Risk Management Consultant
Crown Jewel Insurance

Mary Guzman is an insurance industry veteran and pioneer. She has over 25 years experience advising clients on a myriad of risks to their businesses, most recently with a focus on all things related to technology, media, and intellectual property. Mary is an industry trailblazer and disrupter. Mary was one of the first in the industry to develop a cyber insurance policy in 2000. She is a published author and speaker, having done over 125 speaking engagements on risks/solutions to threats arising from the convergence of all things intangible. She has been a government liaison as part of the DHS cybersecurity and insurance working group during the Obama administration. She is part of the Trade Secret committee of the American Intellectual Property Legal Association (AIPLA). She is also on the board of the USIPA and has been tasked with starting/Chairing the Trade Secret committee for them

 

Matthew Hulse

Associate General Counsel
Intel Corporation

Matthew Hulse

Associate General Counsel
Intel Corporation

Matthew Hulse

Associate General Counsel
Intel Corporation
 

Jeff Pade

Partner
Paul Hastings LLP

Jeff Pade

Partner
Paul Hastings LLP

Jeff Pade

Partner
Paul Hastings LLP
 

Matt Murphy

Partner
Axinn Veltrop & Harkrider LLP

Matt Murphy

Partner
Axinn Veltrop & Harkrider LLP

Matt Murphy

Partner
Axinn Veltrop & Harkrider LLP
2022 Agenda
Interview: Alexander Schinagl, Co-Founder & CTO, OncoOne
 

Florian Lachenmeier

Head of Compliance
Crypto Finance AG

Education:

M.A. HSG in Accounting and Finance. Swiss Certified Public Accountant. Licensed Audit Expert. Lead Auditor for Banks and Securities Dealer

 

Experience:

Florian Lachenmeier

Head of Compliance
Crypto Finance AG

Florian Lachenmeier

Head of Compliance
Crypto Finance AG

Education:

M.A. HSG in Accounting and Finance. Swiss Certified Public Accountant. Licensed Audit Expert. Lead Auditor for Banks and Securities Dealer

 

Experience:

Since January 2023: Crypto Finance Group: Head of Compliance. 2018-2022: Geissbühler Weber & Partner (gwp) Focus: licensing, risk management, compliance, investigations. 2017: Swiss Financial Market Supervisory Authority Secondment Supervisory team large banks (Focus: compliance, conduct, COO). 2007-2018: Deloitte AG Assurance and Advisory Financial Services Industry. 2005: UBS Accounting & Reporting in the Wealth Management & Business Banking division

Francesca Hodges

   I am delighted to be involved with AMR Connect as I believe it's a well thought out event that aims to deliver the key message that AMR is a multifactorial issue that needs immediate attention. In particular, I liked the        inclusion of a showcase for innovative companies developing antimicrobial products in the AMR space and the show of support for drug development in this area. I also appreciated the inclusion of non-traditional antimicrobial approaches and the holistic attitude in including a policy focussed session.   

Francesca Hodges

I am delighted to be involved with AMR Connect as I believe it's a well thought out event that aims to deliver the key message that AMR is a multifactorial issue that needs immediate attention. In particular, I liked the inclusion of a showcase for innovative companies developing antimicrobial products in the AMR space and the show of support for drug development in this area. I also appreciated the inclusion of non-traditional antimicrobial approaches and the holistic attitude in including a policy focussed session.